Associated Papers
Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.
Geng H et al.
Blood Advances, 2025
39536287 (PubMed )
Supplement: BLOODA_ADV-2024-014460-mmc1.pdf
Diagnostic potential of vitreoretinal lymphoma by detection of gene mutations with NGS in 25 Chinese patients.
Chen K et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2024
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Gao F et al.
Cancer Medicine, 2023
36971051 (PubMed )
Supplement: CAM4-12-10267-s001.xlsx › Sheet1
Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T et al.
Frontiers in Oncology, 2022
36465410 (PubMed )
Supplement: DataSheet_1.xlsx › Supplementary_table_4
Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.
Gao F et al.
Frontiers in Genetics, 2021
34925435 (PubMed )
Supplement: DataSheet2.xlsx › Sheet1
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W et al.
Bmc Cancer, 2020
32736575 (PubMed )
Supplement: 12885_2020_7198_MOESM5_ESM.xlsx › Table_S3
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA et al.
The Journal of Investigative Dermatology, 2018
CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y et al.
Human Pathology, 2014
Select a paper to view details